European PRAC concludes safety signal of anaphylaxis with COVID-19 Vaccine AstraZeneca, European Medicines Agency
Following a review of the available data, the European PRAC has recommended an update to the product information to include anaphylaxis and hypersensitivity as side effects and to update the existing warning to reflect that cases of anaphylaxis have been reported. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 15, 2021 Category: Consumer Health News Source Type: news
Rates of Acute Allergic Reactions to COVID-19 Vaccines Extremely Low
THURSDAY, March 11, 2021 -- Severe reactions consistent with anaphylaxis have occurred among 2.47 per 10,000 health care workers receiving COVID-19 vaccinations, according to a research letter published online March 8 in the Journal of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news
Real world data reveal risks of allergic reactions after receiving COVID-19 mRNA vaccines
(Massachusetts General Hospital) Among 52,805 health care employees who received mRNA COVID-19 vaccines, 2% experienced allergic reactions, and anaphylaxis occurred at a rate of 2.47 per 10,000 individuals. All vaccine recipients who experienced anaphylaxis recovered without going into anaphylactic shock or requiring a breathing tube. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 9, 2021 Category: Infectious Diseases Source Type: news
First anaphylaxis case from a deodorant spray including lysozyme chloride - Muramatsu R, Saga M, Muramatsu K.
[The publisher has not provided an abstract for this article.]
Language: en... (Source: SafetyLit)
Source: SafetyLit - March 4, 2021 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news
Covid vaccine side effects: Anaphylaxis is a rare but life-threatening reaction
CORONAVIRUS vaccines are hastening the end of the pandemic, with hospital ICU rates plummeting. Most people getting the Pfizer/BioNTech vaccine will experience mild side effects at most. In very rare instances, anaphylaxis may occur - what is it? (Source: Daily Express - Health)
Source: Daily Express - Health - March 2, 2021 Category: Consumer Health News Source Type: news
Covid vaccine side effects: Anaphylaxis is a rare but severe allergic reaction
CORONAVIRUS vaccines are hastening the end of the pandemic, with hospital ICU rates plummeting. Most people getting the Pfizer/BioNTech vaccine will experience mild side effects at most. In very rare instances, anaphylaxis may occur - what is it? (Source: Daily Express - Health)
Source: Daily Express - Health - March 2, 2021 Category: Consumer Health News Source Type: news
1998 to 2018 Saw Jump in Admissions for Food-Induced Anaphylaxis
THURSDAY, Feb. 18, 2021 -- From 1998 to 2018, there was an increase in hospital admissions for food-induced anaphylaxis in the United Kingdom, according to a study published online Feb. 17 in The BMJ.
Alessia Baseggio Conrado, Ph.D., from Imperial... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 18, 2021 Category: Pharmaceuticals Source Type: news
Hospitalizations for Food Anaphylaxis Triple, but Deaths Down Hospitalizations for Food Anaphylaxis Triple, but Deaths Down
Cow ' s milk is the leading cause of fatal anaphylaxis among children, new data show.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - February 18, 2021 Category: Emergency Medicine Tags: Allergy & Clinical Immunology News Source Type: news
No provision of insurance for recipients of COVID-19 vaccine: Ashwini Choubey, MoS for Health
Measures have been put in place like availability of anaphylaxis kits at each vaccination site, immediate referral to AEFI management centre and observation of vaccine recipients for 30 minutes at session site for any adverse events so as to ensure timely corrective measure, Choubey said in a written reply. (Source: The Economic Times)
Source: The Economic Times - February 9, 2021 Category: Consumer Health News Source Type: news
Pfizer withdraws vaccine plea as panel seeks India trial data
The panel observed that incidents of serious adverse effects such as palsy and anaphylaxis and the causality of the events with the vaccine were being investigated in some of the countries where these jabs have been administered. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 5, 2021 Category: Pharmaceuticals Source Type: news
COVID Vaccine Anaphylaxis: Who Is at Risk? COVID Vaccine Anaphylaxis: Who Is at Risk?
What ' s the most likely cause of the reported anaphylactic reactions to the COVID vaccines, and how can physicians keep patients safe?Medscape Allergy & Immunology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2021 Category: Consumer Health News Tags: Allergy & Clinical Immunology Viewpoint Source Type: news
COVID-19 vaccination programme, RCGP (updated 28th January 2021)
The latest updates on the COVID-19 vaccine, including: COVID-19 Vaccination FAQs SARS-CoV-2 Vaccination #RCGPLive: COVID-19 vaccination in general practice Clinician FAQs and guidance on COVID-19 vaccine for patients receiving Systemic Anti-Cancer Therapy (SACT) Managing anaphylaxis: guidance for GPs delivering the COVID-19 vaccine (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 29, 2021 Category: Consumer Health News Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3
ENSEMBLE
clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to sever...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021
This report describes cases of anaphylaxis after administration of first doses of the Moderna COVID-19 vaccine during December 21, 2020-January 10, 2021. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - January 28, 2021 Category: American Health Tags: Coronavirus [CoV] MMWR Morbidity & Mortality Weekly Report Vaccination Vaccine Adverse Event Reporting System (VAERS) Vaccines COVID-19 Coronavirus Disease 2019 Source Type: news
